MannKind Corporation

Happy World Diabetes Day! Every day, we at MannKind are inspired by our patients, our people and our providers who raise awareness about diabetes and its treatment options. As we continue to work to give people control of their health and the freedom to live life, we could not do this without your ongoing support. We are driven to find new ways to change lives for the better, and in honor of National Diabetes Month, our MannKind employees are sharing how they are helping others live #lifemorehumann. #WDD #NDAM #WorldDiabetesDay #NationalDiabetesMonth #MannKind

Congratulations to our Chief Financial Officer, Steve Binder, on his award for CFO of the Year by the Los Angeles Business Journal! We are so proud of this incredible achievement and grateful for Steve’s dedication, leadership and expertise at MannKind. https://labusinessjournal.com/cfo2020/

Tune-in to hear our CEO, Michael Castagna share his personal journey and passion for our people, our patients and our product during a recent podcast with Resource Options International, LLC. https://youtu.be/VSjX5tI_psA

This Wednesday, July 22nd, we’re excited to be hosting our National Webinar Series for Healthcare Professionals with Dr. Jennifer Rittenberry, Dr. Jeremy Pettus and MannKind’s Chief Medical Officer and moderator for this event, Dr. David Kendall. Join the conversation and listen to our featured speakers share their key learnings from the @AmericanDiabetesAssociation Scientific Sessions, discuss their perspectives on the challenges and unmet needs in the treatment of diabetes,... and share some of their experience with and their patient’s journeys with Afrezza. To request details for this event, please send us an email at [email protected] We can’t wait to see you all there! #ADA2020 #ADAGoesVirtual #diabetes #ADA #virtualhealth #t1d #t2d Important Safety Information Afrezza (insulin human) Inhalation Powder may cause serious side effects, including sudden lung problems, low blood sugar, decreased lung function, lung cancer, diabetic ketoacidosis, severe allergic reaction, low potassium in your blood and heart failure. Some of these side effects may lead to death. The most common side effects are low blood sugar, cough, and sore throat. Do not use AFREZZA if you have long-term lung problems such as asthma or chronic obstructive pulmonary disease. AFREZZA is not for use in place of long-acting insulin. AFREZZA must be used with long-acting insulin in people who have type 1 diabetes mellitus. AFREZZA is not for use in people who smoke or have recently stopped smoking (less than 6 months). AFREZZA is for adults only. See Full Prescribing Information, including BOXED WARNING, Medication Guide and Instructions for Use on Afrezza.com and at bit.ly/AFRPI and bit.ly/AFRMedGuide.